The biomarkers under analysis included tumor mutation burden (TMB) and number of cancer neoantigens, presence of 131 MHC (HLA) alleles identified by WES, homozygous state of HLA genes and their superfamilies which were previously associated with response to PD(L)1 ICI therapeutics in melanoma (40). This evidence concerns the gene HLA-C and cancer.